Noboru Hattori

Prof. Noboru Hattori

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Respiratory Medicine
Verified
Journal Article
Closed access
SOShinichiro Ohshimo
Shinichiro Ohshimo
NINobuhisa Ishikawa
Nobuhisa Ishikawa
YHYasushi Horimasu
Yasushi Horimasu
NHNoboru Hattori
Noboru Hattori
NHNOBUYUKI HIROHASHI
NOBUYUKI HIROHASHI
UCUlrich Costabel
Ulrich Costabel

28 January 2011 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
TMTakeshi Masuda
Takeshi Masuda
NHNoboru Hattori
Noboru Hattori
AHAkinobu Hamada
Akinobu Hamada
HIHiroshi Iwamoto
Hiroshi Iwamoto
SOShinichiro Ohshimo
Shinichiro Ohshimo
NKNobuoki Kohno
Nobuoki Kohno

9 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KOKeitaro Omori
Keitaro Omori
NHNoboru Hattori
Noboru Hattori
TSTadashi Senoo
Tadashi Senoo
YTYusuke Takayama
Yusuke Takayama
TMTakeshi Masuda
Takeshi Masuda
NKNobuoki Kohno
Nobuoki Kohno
Transforming growth factor-β (TGF-β) is central during the pathogenesis of pulmonary fibrosis, in which the plasminogen activator inhibitor-1 (PAI-1) also has an established role. TGF-β is also known to be the strongest inducer of PAI-1. To investigate the link between PAI-1 and TGF-β in fibrotic processes, we evaluated the effect of SK-216, a PAI-1-specific inhibitor, in TGF-β-dependent epithelial-mesenchymal transition (EMT) and fibroblast to myofibroblast differentiation. In human alveolar epithelial A549 cells, treatment with TGF-β induced EMT, whereas co-treatment with SK-216 attenuated the occurrence of EMT. The inhibition of TGF-β-induced EMT by SK-216 was also confirmed in the experiment using murine epithelial LA-4 cells. Blocking EMT by SK-216 inhibited TGF-β-induced endogenous production of PAI-1 and TGF-β in A549 cells as well. These effects of SK-216 were not likely mediated by suppressing either Smad or ERK pathways. Using human lung fibroblast MRC-5 cells, we demonstrated that SK-216 inhibited TGF-β-dependent differentiation of fibroblasts to myofibroblasts. We also observed this inhibition by SK-216 in human primary lung fibroblasts. Following these in vitro results, we tested oral administration of SK-216 into mice injected intratracheally with bleomycin. We found that SK-216 reduced the degree of bleomycin-induced pulmonary fibrosis in mice. Although the precise mechanisms underlying the link between TGF-β and PAI-1 regarding fibrotic process were not determined, PAI-1 seems to act as a potent downstream effector on the pro-fibrotic property of TGF-β. In addition, inhibition of PAI-1 activity by a PAI-1 inhibitor exerts an antifibrotic effect even in vivo. These data suggest that targeting PAI-1 as a downstream effector of TGF-β could be a promising therapeutic strategy for pulmonary fibrosis.

1 April 2003
Verified
Journal Article
Closed access
NINaoya Ikeda
Naoya Ikeda
YNYoshiyuki Nakajima
Yoshiyuki Nakajima
TTTakahiro Tokuhara
Takahiro Tokuhara
NHNoboru Hattori
Noboru Hattori
MSMasayuki Sho
Masayuki Sho
MMMasayuki Miyake
Masayuki Miyake

1 November 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
TMTakeshi Masuda
Takeshi Masuda
NHNoboru Hattori
Noboru Hattori
TSTadashi Senoo
Tadashi Senoo
SAShin Akita
Shin Akita
NINobuhisa Ishikawa
Nobuhisa Ishikawa
NKNobuoki Kohno
Nobuoki Kohno
Plasminogen activator inhibitor-1 (PAI-1), which can be produced by host and tumor cells in the tumor microenvironment, is intimately involved in tumor progression. In the present study, to pursue the possibility that PAI-1 could be a therapeutic target in the management of malignancy, SK-216, a specific PAI-1 inhibitor, was orally administered to wild-type mice that were subcutaneously implanted or intravenously injected with either PAI-1–secreting Lewis lung carcinoma (LLC) or PAI-1–nonsecreting B16 melanoma cells. The systemic administration of SK-216 was found to reduce the size of subcutaneous tumors and the extent of metastases, regardless of PAI-1 secretion levels from the tumor cells. SK-216 also reduced the extent of angiogenesis in the tumors and inhibited VEGF-induced migration and tube formation by human umbilical vein endothelial cells in vitro. Then, to determine whether host or tumor PAI-1 was more crucial in tumor progression and angiogenesis, PAI-1–deficient or wild-type mice were subcutaneously implanted or intravenously injected with LLC or PAI-1 knockdown LLC cells. Tumor progression was shown to be controlled by the presence of host PAI-1 and not affected by the PAI-1 levels in the tumors. Similarly, host PAI-1 played a more crucial role in tumor angiogenesis than did tumor PAI-1. These observations suggest that regardless of the PAI-1 levels in the tumor, the systemic administration of SK-216 exerts an antitumor effect through its interaction with host PAI-1. This antitumor effect might be mediated by the antiangiogenic properties of SK-216. Mol Cancer Ther; 12(11); 2378–88. ©2013 AACR.

31 May 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
YTYusuke Takayama
Yusuke Takayama
NHNoboru Hattori
Noboru Hattori
HHHironobu Hamada
Hironobu Hamada
TMTakeshi Masuda
Takeshi Masuda
KOKeitaro Omori
Keitaro Omori
NKNobuoki Kohno
Nobuoki Kohno
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor that secretes various angiogenic factors. The main inhibitor of plasminogen activators, PAI-1 (SERPINE1), has been implicated in tumor progression and angiogenesis, and high PAI-1 expression has been associated with poor prognosis in MPM patients. In this study, we examined the antiangiogenic effects of PAI-1 inhibition in MPM. We administered the PAI-1 inhibitor, SK-216, to orthotopic mouse models in which MPM cells expressing high levels of VEGF (VEGFA) or bFGF (FGF2) were intrapleurally transplanted. SK-216 administration reduced tumor weights and the degree of angiogenesis in intrapleural tumors, irrespective of their angiogenic expression profiles. In addition, a combination of SK-216 and the chemotherapeutic agent cisplatin significantly reduced tumor weights compared with monotherapy, prolonging the survival of animals compared with cisplatin treatment alone. Furthermore, SK-216 inhibited migration and tube formation of cultured human umbilical vein endothelial cells induced by various angiogenic factors known to be secreted by MPM. These findings suggest that PAI-1 inactivation by SK-216 may represent a general strategy for inhibiting angiogenesis, including for the treatment of MPM. Cancer Res; 76(11); 3285–94. ©2016 AACR.